BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
April 26 2017 - 6:00AM
Business Wire
Conference Call and Webcast on Wednesday, May
10, 2017, at 4:30 p.m. ET / 1:30 p.m. PT
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology
company developing and commercializing products addressing
degenerative diseases, today announced that it will release first
quarter financial and operating results on Wednesday, May 10, 2017,
after the close of the U.S. financial markets. The Company will
host a conference call and webcast on Wednesday, May 10, 2017, at
4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the
results and recent corporate developments.
The conference call dial-in number in the U.S./Canada is 1-877-
407-0784. For international participants outside the U.S./Canada,
the dial-in number is 1-201 689-8560. For all callers, please refer
to the “BioTime, Inc. Conference Call.” The live webcast can be
accessed on the “Events & Presentations” page of the “Investors
& Media” section on the company’s website at
http://www.biotimeinc.com/.
A replay of the conference call will be available for seven
business days beginning about two hours after the conclusion of the
live call, by calling toll-free from U.S./Canada: 1-844-512-2921;
international callers dial 1-412-317-6671. Use the Conference ID
13661114. Additionally, the archived webcast will be available on
the “Events & Presentations” page of the “Investors &
Media” section on the company’s website at
http://www.biotimeinc.com/.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company
focused on developing and commercializing novel therapies developed
from what the company believes to be the world’s premier collection
of pluripotent cell assets. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are
capable of becoming any of the cell types in the human body.
Pluripotent cells have potential application in many areas of
medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for
which there presently are no cures. Unlike pharmaceuticals that
require a molecular target, therapeutic strategies based on the use
of pluripotent cells are generally aimed at regenerating or
replacing affected cells and tissues, and therefore may have
broader applicability than pharmaceutical
products. BioTime also has significant equity holdings in
two publicly traded companies, Asterias Biotherapeutics,
Inc. and OncoCyte Corporation,
which BioTime founded and which, until recently, were
majority-owned consolidated subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170426005476/en/
Investor Contact:EVC Group, Inc.Brian Moore,
310-770-0389bmoore@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2024 to May 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to May 2024